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Abstract
Introduction: Patellar tendon overuse injuries are common in athletes. Imaging may show a change in tissue
structure with tendon thickening and disruption of the intratendinous substance. We wish to test the hypothesis
that both autologous bone marrow expanded mesenchymal stem cells and autologous leukocyte-poor platelet-rich
plasma (LP-PRP) implanted into the area of the disrupted tendinopathic patellar tendon will restore function, but
tendon regeneration tissue will only be observed in the subjects treated with autologous bone marrow expanded
mesenchymal stem cells.
Methods and analysis: This is a single-centre, pilot phase I/II, double-blinded clinical trial with randomisation with
active control. Twenty patients with a diagnosis of patellar tendinopathy with imaging changes (tendon thickening
and disruption of the intratendinous substance at the proximal portion of the patellar tendon) will be randomised
in a 1:1 ratio to receive a local injection of either bone-marrow autologous mesenchymal stem cells (MSC), isolated
and cultured under GMP at The Institute of Biology and Molecular Genetics (IBGM) (Spain) or P-PRP. The study will
have two aims: first, to ascertain whether a clinically relevant improvement after 3, 6 and 12 months according to
the visual analogue scale (VAS), Victorian Institute of Sport Assessment for patellar tendons (VISA-P) and
dynamometry scales (DYN) will be achieved; and second, to ascertain whether the proposed intervention will
restore tendon structure as determined by ultrasonography (US), Doppler ultrasonography (DUS), and innovative
MRI and ultrasound techniques: Magnetic Resonance T2 FAT SAT (UTE, Ultrashort Echo TE) sequence and
Ultrasound Tissue Characterization (UTC). Patients who are randomised to the P-PRP treatment group but do not
achieve a satisfactory primary endpoint after 6 months will be offered treatment with MSC.
Trial registration: NCT03454737.
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Background
Overload patellar tendon injuries are common in elite
athletes (7 to 45%) and activities where repetitive jump-
ing is required [1–4]. Pain may become recurrent and
refractory to any conservative management, leading to a
sports-related or occupational disability [5]. The patho-
genesis of patellar tendinopathy is still elusive, but a
failed healing response remains at its basis [6, 7]. At the
time of surgery, typically no inflammatory cells or in-
flammatory mediators are detected in the tendon tissue,
suggesting that tendinopathy is not the result of typical
inflammation [8, 9]. Poor vascularization is often re-
ported as a factor that contributes to tendinopathy, but
tendinopathy is often associated with neovascularization
and increased blood-flow through the tendon, which
might be a restorative and beneficial response [10]. Al-
though the source of pain has not been defined [11], in
some studies small substance P-positive nerve fibres are
closely related to the neovascularization process and
may transmit pain perception [6, 12–14].
Other pathological changes related to patellar tendino-
pathy include (a) intra-tendinous calcification; (b)accumu-
lation of adipose cells; (c) disruption and disorganisation
of collagen fibres; (d) conversion of type I collagen to type
III collagen; (e) a reduction in number of fibroblasts; (f)
changes in tenocyte morphology; and (g) an increase in
proteoglycan and glycosaminoglycan content [6].
Although the accepted standard treatment for patellar
tendinopathy is a graded rehabilitation programme, not
all patients respond to exercise therapy [15]. Medical or
surgical management may provide improvement in
symptoms but does not result in regeneration of normal
tendon tissue [16]. Recently, MSC have been shown to
promote tendon healing in an animal model of acute
tendon injury [17, 18]. In addition, these cells may con-
trol inflammation by influencing differentiation, migra-
tion or apoptosis in different immune cells [19–25].
MSC have the following distinctive features: (a) ability
to differentiate into osteoblasts, adipocytes and chondro-
cytes in vitro; (b) ability to adhere to plastic during cul-
ture; (c) more than 90% of the cells show a positive
immunophenotype for CD73, CD105, CD90 and CD166
antigens; less than 10% of the cells show a positive
immunophenotype for CD45, CD14, CD34, CD31 and
HLA-DR antigens [26]. MSCs are found in several or-
gans and tissues, where they may be harvested. Never-
theless, bone marrow is the optimal and most easily
accessible source of MSC. Once obtained, these cells can
be isolated and grown ex vivo under pharmaceutical
standards and used in human therapies known as an ‘ad-
vanced therapy medicine’ [27]. Our research group has
used MSC successfully in several osteoarticular injuries
[28–36]. Given the immunomodulatory and anti-
inflammatory abilities of MSC, harvesting and grafting
these cells into an area affected by patellar tendinopathy
are feasible options that may provide satisfactory results.
The use of autologous leukocyte-poor platelet-rich
plasma (LP-PRP) in tendon injuries is well established
[37], including patellar tendon injuries, at times showing
good clinical response [38, 39]. Our research group has
also successfully used this approach in various musculo-
skeletal conditions in several areas of the human body
[40, 41]. A recent systematic review and meta-analysis
[42] demonstrated improved outcomes with the use of
leukocyte-rich-PRP (LR-PRP) compared to LP-PRP.
We wish to test the hypothesis that an analgesic effect
will be achieved using either treatment, but significant
regeneration of tendon tissue will only be achieved in
the cell therapy group. We will assess clinical results by
clinical examination, visual analogue scale (VAS), the
validated Spanish version of VISA-P43 and manual dyna-
mometry. We will evaluate tissue regeneration using sev-
eral imaging techniques. The use of MRI with a UTE
sequence in the sagittal plane makes it possible to deter-
mine tendon tissue features at very low T2 values in all
regions, including the ‘gap’ and healthy tendon tissue. In
addition, UTE sequences allow to visualize and delineate
defects that are not detected by conventional imaging.
UTC is an innovative imaging technique for assessing
tendon injuries. Using a conventional ultrasound device,
600 axial sections of the tendon are performed at
0.2 mm intervals and compounded to form a 3D image.
Using this technique, collagen fibre alignment may be
quantified into four different types: (a) normal aligned
fibrillar structure; (b) slightly misaligned fibrillar struc-
ture; (c) disorganised fibrillar structure; (d) complete dis-
integration of tendon tissue [43]. Ultrasonography is the
most accessible imaging technique used to confirm the
clinical diagnosis and determine the exact location of
the lesion. Ultrasonography also helps calculate tendon
size, defines eco-texture, allows measurement of any ten-
don gaps in several planes and assesses the degree of
tendon vascularization. In addition, ultrasonography al-
lows to dynamically monitor tendon function [44].
Should the results be better for the cell therapy group,
the patients in the active control group (who were
injected with LP-PRP) who have not achieved similar
benefits to those of patients in the MSC group after
6 months will be offered cell therapy. We believe that
this will increase the feasibility of the clinical trial.
Characteristics of the MSC intervention
MSCs exhibit the typical stem cell features defined by the
International Society of Cellular Therapy [23]. MSC are an
advanced therapy drug registered with the Agencia Espa-
ñola de Medicamentos y Productos Sanitarios (AEMPS)
with IND number 10–134. They are bone marrow MSC,
processed according to the GMP practices at the IBGM
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and re-suspended in an isotonic medium composed of
Ringer lactate solution, 0.2% human serum albumin and
5mM glucose. The product is supplied by the laboratory
after a 23-day processing period. Cell viability is ≥ 90%, and
negative microbiological results are obtained for Gram and
Mycoplasma microorganisms. Endotoxin levels are below
0.5 IU/mL. The product is stable for 8 h at 4–12 °C. The
product is supplied in two 5 mL syringes, one containing
10 × 106 MSC suspended in a 2 mL solution, and the other
containing 10 × 106 MSC suspended in a 4 mL solution.
The total dose of cells supplied is 20 × 106 ± 2 × 106 MSC.
General characteristics of P-PRP intervention
LP-PRP is obtained under strict aseptic conditions.
Blood components are fractioned by centrifugation. In a
surgical environment, peripheral venous blood is col-
lected into four 9 mL citrate tubes. The anticoagulated
blood is centrifuged at 1,200 rpm for 8 min (460g). Six
milliliters of LP-PRP are obtained from a 36-mL sample
of autologous peripheral venous blood. The LP-PRP sus-
pension contains a two-fold increase in the number of
platelets compared to peripheral blood and a very low
number of leukocytes (average basal peripheral blood
228 × 103 platelets/mm3, range 165–329 × 103; LP-PRP:
563 × 103 platelets/mm3; range 407–801 × 103). Before
application, plasma coagulation is activated by adding
5% CaCl2 [38, 45].
Methods/design
Main objectives
1. To assess the clinical efficacy of MSC injection and
compare the results with those obtained in the LP-
PRP group. Outcomes will be assessed using sub-
jective patient reports, VAS and VISA-P scales, and
strength determination of the extensor muscle
group using manual dynamometry (DYN).
2. To confirm changes in the architecture for
regeneration of the patellar tendon gap following
peritendinous and intratendinous injection of MSC
and compare these results with those obtained in
the LP-PRP group. Assessment will be performed
using UTE-MRI, UTC and ultrasonography.
Secondary objectives
To assess the viability and safety of the use of medical
devices MSC and LP-PRP when injected into the patellar
tendon; prove that all procedures described in the
present protocol are feasible; and register potential ad-
verse events related to either treatment, as well as any
other adverse events that occur during the clinical trial,
whether related to the trial or not.
Trial design
Study population
Twenty male recreational athletes with a patellar tendi-
nopathy who meet the inclusion and exclusion criteria
will be recruited and will be followed for 1 year (Fig. 1).
Inclusion criteria:
1. Male participants aged between 18 and 48
2. Pain and tenderness at the area of attachment of
the patellar tendon on the lower pole of the patella
[46] for more than 4 months, with no clinically
relevant response after conservative treatments
3. US confirming disruption ≥ 3 mm of the fibrillar
structure in the proximal portion of the patellar
tendon, tendon thickening and a hypoechoic injury
MRI of the patellar tendon in T2 FAT SAT sequence
(fat saturation) showing an increase of ≥ 3 mm in
longitudinal diameter at the proximal insertion
4. Informed signed written consent by the participant
5. The participant is able to understand the nature of
the study.
Exclusion criteria:
1. Participant younger than 18 (or legally dependent)
or over 48 years of age
2. MRI with a grade III–IV osteochondral lesion in
any compartment of the knee
3. Injury to the anterior or posterior cruciate ligament
4. Local injection with corticosteroid during the
previous 12 months
5. Local injection with PRP during the previous
6 months
6. Evidence of local or systemic infection
7. Patients presenting with positive serology to HIV
1 or 2, hepatitis B (HBsAg, HBcAc), hepatitis C
(anti-HCV-Ab) and syphilis
8. Congenital or acquired conditions involving
malformation and/or significant deformation of the
knee that hampers the administration of the
planned intervention and evaluation of the results
9. Body mass index (BMI) greater than 30. 5
(obesity grade II)
10. Active neoplastic disease
11. Immunosuppression
12. Simultaneous participation in another clinical trial
or treatment with another research product during
the 30 days prior to inclusion in the study
13. Other pathologies or circumstances that may
compromise participation in the study according to
medical criteria.
Patients will be randomized by the Clinical Research
Organization (CRO) (Adknoma) using SAS statistical
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software (version 9. 4) into either the MSC group or
PRP group in a 1: 1 ratio. After randomization, ei-
ther MSC or LP-PRP will be injected intralesionally
and around the affected area of the patellar tendon.
To keep patients and evaluating physicians blind to
treatment, sham procedures will be performed in
both groups (i.e. the MSC group will have blood
extracted and will have their tendon injected with
normal saline at the first stage of treatment, and the
LP-PRP group will undergo a sham bone marrow
harvesting at the first stage of treatment). The treat-




Ten patients will be treated with saline solution (sham)
and with 20 × 10E6 MSC after 23 days.
Stage one
1. Under sterile conditions, a total of 4 citrate tubes
(9 mL per tube; total volume 36 mL) of venous
blood are withdrawn from the antecubital vein of
the non-dominant arm as a sham procedure of P-
PRP preparation.
2. With the patient prone, and after sedation induced
by midazolam and propofol, local anaesthetic
Fig. 1 Study flow chart
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injections (lidocaine 1%; 10 mL) are administered in
both the posterior superior iliac crests and are
penetrated using an 11 gauge trocar. Using
sequential aspirations of 1–2 mL each, 100 mL of
bone marrow is collected in a heparinized container
to be sent to IBGM for isolation and culture of
MSC.
3. The patient is then positioned supine. Under
ultrasonography guidance, 1 mL of normosaline
solution is injected using a 22 gauge needle in the
tendinous and 1 mL in the paratendinous medial
and lateral areas of the patellar tendon. The
participant is then transferred to the postoperative
recovery room, where they remain for 1 h before
discharge.
Stage two (after 23 days)
1. Under sterile conditions, a total of 4 citrate tubes
(9 mL per tube; total volume 36 mL) of venous
blood are withdrawn from the antecubital vein of
the non-dominant arm as a sham procedure of
P-PRP preparation.
2. With the patient supine under sedation with
midazolam and propofol, under ultrasonography
guidance, a 2-mL solution containing 10 × 106
MSV is injected into the tendon; a 2-mL solution
containing 5 × 106 MSC is injected into the
medial peritendinous area, and a 2-mL solution
containing 5 × 106 MSC is injected into the
lateral peritendinous area.
LP-PRP control group
Ten patients will be treated with two doses of LP-PRP,
each containing 6 mL of solution-PRP. The second dose
will be injected 23 days after the first one.
Stage one
1. Under sterile conditions, a total of 4 citrate tubes
(9 mL per tube; total volume 36 mL) of venous
blood are withdrawn from the antecubital vein of
the non-dominant arm for P-PRP preparation. One
to two supplementary tubes of peripheral venous
blood are withdrawn for preservation in a serum
bank for security reasons. LP-PRP is prepared
according to ITRT’s PRP protocol.
2. With the patient prone, and after sedation induced
by midazolam and propofol, 10 mL of lidocaine 1%
is administered in the posterior superior iliac
crests, and an 11-gauge trocar is inserted in the
subcutaneous tissue as part of the sham procedure
for obtaining MSC.
3. With the patient supine, and sedation induced by
midazolam and propofol, using ultrasound guidance,
2 mL of LP-PRP are injected intratendinously, 2 mLof
LP-PRP are injected into the medial peritendinous
area, and 2 mL of LP-PRP are injected in the lateral
peritendinous zone adjacent to the area of
tendinopathy.
Second stage (after 23 days)
1. The procedure for obtaining blood and LP-PRP
preparation is performed again under sterile
conditions.
2. With the patient supine, and sedation induced by
midazolam and propofol, using ultrasound
guidance, 2 mL of LP-PRP are injected intratendi-
nously, 2 mL of LP-PRP are injected into the medial
peritendinous area, and 2 mL of LP-PRP are
injected in the lateral peritendinous zone adjacent
to the area of tendinopathy.
Experimental phase B
Results will be evaluated 6 months after the treatment. If
the results support the hypothesis that a higher efficacy
is obtained in the MSC group, the cell therapy trial will
be offered to subjects from the LP-PRP group who show
no evidence of clinically relevant improvement: if they
wish, this group will be treated with MSC. This will be
‘experimental phase B’, which will be evaluated with
the same clinical and imaging assessment protocol as
described above.
Post-treatment procedures (rehabilitation program)
The participants will be discharged 1 h after injection of
the cell suspension or LP-PRP solution and advised to
rest for 48 h. Analgesia (ibuprofen 600 mg, every 8 h,
and omeprazole 20 mg once daily) are prescribed for the
participant to self-administer if needed.
After treatment, a specific rehabilitation protocol will
be followed, applying appropriate progressive load to the
affected limb [6]. Table 1 shows the rehabilitation pro-
gram over 3 months. For greater details, please refer to
Malliaras et al 2015 [15] and Mascaro et al. 2018 [47].
After the 3 months, and after evaluating each patient by
physical examination, US and MRI, the athletes will be
progressively allowed to gradually return to their sport.
The follow-up consists of clinical examination visits
and image monitoring by ultrasonography and by UTC,
MRI-UTE, as specified in the protocol schedule.
Concomitant medications
Any concomitant medications administered from the
day of the initial treatment until the end of the trial will
be recorded. No fluoroquinolone-based antibiotic drugs
will be administered during the entire study period [48,
49]. If they must be administered, the subject will be ex-
cluded from the clinical trial and will continue therapy
using standard treatments. Corticosteroids or anti-
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inflammatory therapy should not be administered. If
they must be administered, the patient will not be ex-
cluded from the trial, but the administration will be re-
corded in the clinical records. If necessary, treatment
with ibuprofen 600 mg will be allowed.
Response evaluation
Subsequent assessments following the treatment include
AE review, VAS (pain), VISA-P Questionnaire, ultra-
sound imaging (conventional ultrasound, UTC and
MRI), dynamometry manual test and clinical assessment
(Table 2 for phase A, and Table 3 for phase B). These
will take place at 1, 2, 3, 6, 8 and 10 weeks and 3, 6,
12 months post-treatment.
Adverse events
Possible adverse events occurring during the trial period
(regardless of whether they are related to the procedure)
will be recorded and tabulated. In the event of a serious
adverse effect, a notification will be sent to the Spanish
agency for Medicines and Healthcare Products (AEMPS)
through the Clinical Research Organization (CRO), ac-
cording to established procedures and terms.
Pain and function
Pain will be recorded on the VAS, and function will be
evaluated by measuring extension forces in the knee
using a manual dynamometer.
The pain and functional evaluation will be performed
using the VISA-P score, which specifically evaluates pain
and function in patellar tendinopathy. The scale ranges
from 0 to 100, where a value of 100 indicates the ab-
sence of pain at rest, when walking, when climbing up
or downstairs or during exercise [50]. VISA-P score
values for patients with chronic patellar tendinopathy
usually range from 30 to 50. Physical activity may be
undertaken again if values are above 60. Patients with
score values over 70 are considered fit for competition,
although demands are higher for professional athletes.
The minimum significant difference has been set at 13
points.
The following VISA-P criteria are used to assess
improvement in this trial [51]:
– Desired: ≥ 60/100 (after 3 months)
– Very satisfactory: ≥ 70/100 (after 6 months)
– Ideal: ≥ 80/100 (after 12 months)
Ultrasonography
Ultrasound scanning will be performed with an Aplio
500 (TUS-500 5.0 Platinum Series, manufactured by
Canon Medical Systems Corporation in Nasu, Japan)
using a high-frequency linear array probe (PLT 1005BT),
5.0–14 MHz frequency range. The most commonly used
2D frequency will be differential harmonic of 14 MHz
(diff THI 14 MHz). The depth used will be 5 cm, with a
single focus at 1.8 cm and a dynamic range of 65 dB
The patellar tendon will be examined longitudinally
and transversely using greyscale and colour measures,
exerting the least possible pressure with the probe. Im-
ages will be recorded in static and dynamic formats.
Therapeutic results will be regarded as positive if
the following findings will be evidenced: improvement
in tendon echotexture, gap reduction and reduced
neovascularization.
A change in thickness will also be considered, but to a
lesser extent, as the significance of thickness change in
terms of success of any intervention programme is un-
known [44].
The following will be determined:
Table 1 Rehabilitation program over 3 months
Rehabilitation program Day 0–3 4–5 days 2–3 weeks 4–8 weeks 3 months
RICE
Isometric squat against wall 5 reps × 30–40 s (3’ rest).
Progress from 45° to 90° knee flex)
Cycling (alternate days) 15–30 min 15 min
Isometric leg extension 30° 8 reps × 45'' (1’ rest)
Elliptical training (alternate days) 15 min
Slow dynamic knee extension
(Con/Ecc)
4'' Con/4'' Ecc, 30'' rest. Increase
load from 2 to 12 kg. Progress
from bilateral to unilateral
Numeric rate score (NRS) allowed < 4/10, if > 4/10 stop progression
load for 2–3 days
Running Progressively
Plyometrics Progressive jumps landing to
plyometrics. Every 3 days
Fast dynamic exercise (Con/Ecc) 3 × 6–8 reps, 1–3' rest
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1. Lesion location (medial, central, lateral) and
(anterior, central, posterior).
2. Tendon thickness 5 mm distal to the inferior pole
of the patella.
3. Eco-texture (using a 0–3 scale).
4. Longitudinal and axial “gap” measures; area value.
5. Vascularization degree I–V
UTC
Tendon eco-structure will be evaluated according to
four subtypes I, II, II and IV in cross-section of region of
interest (ROI): percentage of each subtype will be calcu-
lated. The distance (mm) from the lower patellar pole in
the anteroposterior section and cross-section will also be
measured (based on percentage points).
Subtype I is regarded as ideal, corresponding to a per-
fectly aligned fibrillar structure; Subtype IV is regarded
as the most sub-optimal, corresponding to the absence
of fibrillar structure. To establish a healing standard, the
4 aforementioned subtypes will be assessed, and changes
will be evaluated by calculating the relative increase in
percentage points of subtypes I and II (indicative of
organised tissue), along with the relative decrease in per-
centage points of subtypes III and IV (indicative of dis-
organised tissue).
MRI
Regarding MR, we shall use a 3D sequence using a Toshiba
TITAN 3T MRI (Canon Medical Systems, Corporation in
Table 2 Outcome assessments experimental phase A
Study period
Enrollment Treatment Follow-up




Preop + serology X
Allocation X
ClinicalHistory X X
Physical exam X X X X X X X X X X X
VAS X X X X X X X X X X
















MRI X X* X
Ultrasound X X X X X X X X X X
UTC X X X X X X
DYN X X X X X X
AE X X X X X X X X X X X
Medication X X X X X X X X X X X
Elig. eligibility, IC informed consent; VAS visual analogue scale; VISA-P Victorian Institute of Sport Assessment (Patellar); BM bone marrow harvest; MSC Infusion of
MSC; MRI magnetic Rresonance; UTC ultrasound tissue characterisation; DYN dynamometry, PreOp preoperative study, AE Adverse Events.
X* if the VAS and VISA-P scales show a significant improvement, and MRI, US, and UTC provide evidence of healing, the result will be considered positive and the
patient will be followed up with confirmation controls at 6 and 12 months. For safety reasons, according to AEMPS criteria, a control test will be performed after
the trial, within a period of 2 years after treatment.
If the 6-month evaluation shows negative results, patients may be transferred to the open experimental phase B.
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Nasu, Japan), with a phase 3D MPV Voxel mVox T2
weight, isotropic Voxel (0.6 mm, 90.6 mm and 90.6 mm).
With a T2 FAT SAT sequence (fat saturation) in the
sagittal plane, the dimensions of the intra-tendinous
changes will be measured using several signal character-
istics: hypo-signal, homogeneous signal, heterogeneous
signal, isointense signal, and normal signal. Proximal,
medial and distal areas of altered signal will be measured
in millimetres. Hoffa fat oedema and patellar bone
oedema will also be evaluated. An FFE (Fast FE) 3D se-
quence will be used in the coronal plane to measure the
gap and the gap in cross-section diameter in millimetres.
The presence of calcification will also be assessed. UTE
(Ultrashort Echo TE) sequences will be obtained in the
sagittal plane, and T2 mapping will be acquired in re-
gions of Interest (ROI), and will be established for the
areas of altered signal, in the medial and lateral areas,
and in healthy tendon.
The intra-articular appearance of the knee joint will
also be assessed, with quantification of the degree of ar-
throsis (I–IV) of each knee compartment.
Criteria for non-response to treatment
A lack of response to treatment will be recorded if no clin-
ically relevant improvement or tendon repair changes
occur after a 6-month period. Clinical changes will be
assessed using a combination of physical examination,
VAS score, VISA-P questionnaire and DYN. Tendon re-
pair will be assessed using ultrasonography, UTC and
MRI. A partial response will be considered if there is evi-
dence of either clinical improvement or tendon repair.
Patient and public involvement
Patients and the public were not directly involved with
the development of the current protocol. The primary
research question is the efficacy of the use of culture-
expanded MSCs versus LP-PRP on the treatment of pa-
tellar tendinopathy. This will enable the development of
a larger RCT that will involve oversight from the patient
and public representatives. Patient recruitment is de-
scribed above, and the results will be disseminated to
the participants directly in the doctor's office at the end
of the study.
Statistical analysis
Statistical analysis will be performed using version 21. 0
of the Statistical Package for Social Sciences (SPSS Inc,
Chicago, IL). We will evaluate: (i) adverse events (AE)
and serious adverse events (SAE) showing relationships,
causality and severity will be provided; (ii) frequency and
percentage of AE and SAE; (iii) laboratory results includ-
ing hematologic and biochemistry values will be collated:
leukocytes levels, absolute neutrophils count, platelet
count, creatinine levels, AST (SGOT)/ALT (SGTP)
levels, etc. A list of laboratory parameters will be ob-
tained for each patient and visit and will include refer-
ence range values. Values will be summarized in a basal
and post-basal visit analysis will include the following
Table 3 Outcome assessments experimental phase B
Study period
Enrollment Treatment Follow-up
Timepoints 0 23 days 1 weeks 2 weeks 3 weeks 6 weeks 8 weeks 10 weeks 3 months 18 weeks 6 months 12 months
IC X
Preop + serology X
Physicalexam X X X X X X X X X X X X
VAS X X X X X X X X X X X





MRI X X* X X X
Ultrasound X X X X X X X X X X X
UTC X X X X X X X
DYN X X X X X X X
AE X X X X X X X X X X X X
Medication X X X X X X X X X X X X
VAS visual analog scale; VISA-P Victorian Institute of Sport Assessment (Patellar); BM bone marrow harvest; MSV injection of MSV; MRI magnetic resonance imaging;
UTC ultrasound tissue characterization; DYN dynamometry, PreOp preoperative study, AE adverse Events.
X* this MRI test will establish the status of the healing process at 3 months.
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values: (i) valid ‘n’; (ii) mean; (iii) standard deviation; (iv)
median; (v) minimum and maximum.
The frequency and percentage values of patients show-
ing evidence of tendon regeneration 6 months after
treatment with MSC or P-PRP will be provided.
The following methods will be used to describe and
analyse the results obtained:
1. Descriptive statistics in numerical variables: number
of valid cases; number of non-available values; mean
value; standard deviation; 95% confidence interval
for the mean value; median, minimum and max-
imum values. In discrete and categorical variables,
the following values will be provided: frequency;
percentage value for the total number of valid cases;
percentage value for the total number of non-
available values.
2. Inferential statistics tests for comparing groups and
time points: ANOVA with repeated measures (or
ANCOVA) if covariables with a significant
interaction are detected with their corresponding
contrast values (Scheffe test), or non-parametric
tests if the assumption of normality is rejected
(Mann-Whitney U test for comparison between
groups and Wilcoxon test for comparison between
measurements). The significance level for all statis-
tical analyses will be 0. 05.
Efficiency sample (per protocol (PP) population) in-
cludes all patients whose tendon lesion has been treated
with an MSC or LP-PRP suspension. These patients
must have had no major violations of the protocol, and
at least one assessment of efficacy after treatment.
‘Full analysis set’ (FAS) (intention to treat analysis) in-
cludes all patients in the study, whether they finish the
study or comply with the protocol.
The safety population will be used in the analysis of
the primary endpoint and of all other safety parameters
defined.
A list of all demographic and baseline data will be pro-
vided for each patient. All lists will be provided for FAS
and PP populations.
Discussion
Patellar tendinopathy mainly occurs in young adults
who practise sports, either professionally or as ama-
teurs, which involve repeated running, hopping and
jumping [52], with typical clinical and imaging diag-
nostics features [53].
To minimise uncontrolled factors that could affect the
results, this study only includes male patients, as the
viscoelastic properties of skeletal muscle and tendon are
driven by hormone expression [54]. Disorders of insulin
and thyroid hormones metabolism are related to
tendinopathy both in vitro and in vivo [55], and sex hor-
mones may promote changes in the structure of ten-
dons, thus influencing their response to physical exercise
[56]. If we obtain positive results in this study, a new
study will be performed on female subjects only.
Both the cellular and applied LP-PRP treatments are
based on safety and efficacy criteria obtained in animal
studies and in clinical trials in which these treatments
were applied successfully to treat other musculoskeletal
pathologies [17, 18, 22, 29, 31–33, 41]. Future studies
should try to establish the optimal cellular dose or the
appropriateness of multiple doses. The composition and
volume of the cell suspension medium should also be
noted, as these variables can influence results.
Applying the guidelines of the Helsinki declaration of
the World Medical Association, we have avoided using a
true placebo in the control group, and plan to use an ac-
tive control LP-PRP group. We hypothesise that this
control treatment is very unlikely to exert the significant
regenerative effect that we would attribute to MSC.
However, this hypothesis must be confirmed, as no pre-
vious clinical trials have analysed the therapeutic effect
of expanded BM-MSCs in patellar tendinopathy. The
present study has several trengths. This is the first study
to assess the effect of injecting autologous mesenchymal
cells into the pathological zone of refractory proximal
patellar tendinopathy in athletes. The study will monitor
clinical scores, strength and imaging findings including
2D US, UTE MRI and ultrasound tissue characterization
(UTC). The addition of UTE MRI and UTC will enable
more precise measurement of structural tendon changes
than 2D US. The control group will be offered mesen-
chymal cell therapy if the results of the control group
prove ineffective. We are fully aware of the limitations of
the present study. For example, the control group will
receive active LP-PRP treatment rather than a true pla-
cebo, limiting the value of a control group. However, it
will be easier to recruit athletes in a study with a control
treatment that is perceived to be effective in an athletic
cohort. The sample size is small, limiting the power of
this study. Finally, this study fails to establish an optimal
cell dose, which should be examined in future studies.
It is important to plan a second open experimental
phase, where patients treated with LP-PRP who have not
improved will be offered cell treatment. This approach,
in addition to providing subjects included in the control
group with a potentially more effective treatment, should
also help determine the scope of the therapeutic effect
of the MSC on LP-PRP, establishing a comparative cost-
effective index.
This clinical trial also aims to advance current know-
ledge about the pathology of interest, and the hypothetical
regenerative effect of incorporating innovative diagnostic
systems and evaluations of this type of lesions. Both UTE
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magnetic resonance (Ultrashort Echo TE) and UTC are
innovative non-invasive techniques that allow us to quan-
tify regenerative effects using imaging.
Trial Status
– Protocol version: V2. 05-July 2017
– Recruitment starts December 2017.
– Total subjects recruited on 28-10-2018: 20
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